Home » Stocks » ARDX

Ardelyx, Inc. (ARDX)

Stock Price: $7.15 USD 0.03 (0.42%)
Updated Jun 22, 2021 4:00 PM EDT - Market closed
After-hours: $7.20 +0.05 (0.70%) Jun 22, 7:56 PM
Market Cap 705.77M
Revenue (ttm) 12.94M
Net Income (ttm) -105.10M
Shares Out 97.18M
EPS (ttm) -1.15
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day June 22
Last Price $7.15
Previous Close $7.12
Change ($) 0.03
Change (%) 0.42%
Day's Open 7.15
Day's Range 6.95 - 7.24
Day's Volume 1,095,474
52-Week Range 4.96 - 9.23

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

FREMONT, Calif. and WALTHAM, June 7, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for peo...

2 weeks ago - PRNewsWire

FREMONT, Calif. and WALTHAM, Mass.

4 weeks ago - PRNewsWire

Penny stocks that left the nest in 2021 To Watch Right Now The post Small-Cap & Penny Stocks To Watch In May Hitting It Big In 2021 appeared first on Penny Stocks to Buy, Picks, News and Information | P...

Other stocks mentioned: GTBP, PDSB, VXRT
1 month ago - PennyStocks

Ardelyx (ARDX) delivered earnings and revenue surprises of -6.25% and 498.36%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

1 month ago - Zacks Investment Research

FREMONT, Calif. and WALTHAM, Mass.

1 month ago - PRNewsWire

The FDA pushed back its approval decision for the company's lead candidate.

1 month ago - The Motley Fool

The FDA has extended the Prescription Drug User Fee Act (PDUFA) date for Ardelyx Inc's (NASDAQ: ARDX) tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on...

1 month ago - Benzinga

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 month ago - Zacks Investment Research

FREMONT, Calif. and WALTHAM, Mass.

2 months ago - PRNewsWire

Investors need to pay close attention to Ardelyx (ARDX) stock based on the movements in the options market lately.

2 months ago - Zacks Investment Research

The company's Japanese partner initiated pivotal late-stage studies of Ardelyx's lead candidate.

2 months ago - The Motley Fool

FREMONT, Calif. and WALTHAM, Mass.

2 months ago - PRNewsWire

Ardelyx (ARDX) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down...

2 months ago - Zacks Investment Research

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CLMT, BW, LEAF, PMBC
2 months ago - 24/7 Wall Street

FREMONT, Calif. and WALTHAM, Mass.

3 months ago - PRNewsWire

Ardelyx (ARDX) delivered earnings and revenue surprises of -23.08% and -3.26%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

3 months ago - Zacks Investment Research

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial availabilit...

3 months ago - GlobeNewsWire

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

3 months ago - Zacks Investment Research

FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for people with ki...

4 months ago - PRNewsWire

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider buying can ...

Other stocks mentioned: CAR, CNNE, MPLN, SBTX, SEER
6 months ago - Benzinga

FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and car...

7 months ago - PRNewsWire

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

7 months ago - Zacks Investment Research

I last wrote about Ardelyx as the company was close to submitting its tenapanor NDA and the stock was trading for over $8. Since that time, Ardelyx had gotten its NDA accepted with an April 29, 2021 PDU...

7 months ago - Seeking Alpha

FREMONT, Calif. and TOKYO, Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patients with kid...

8 months ago - PRNewsWire

FREMONT, Calif., Oct. 12, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and ca...

8 months ago - PRNewsWire

Ardelyx Inc. (NASDAQ: ARDX) shares dipped on Tuesday after the firm posted a win with the U.S.

9 months ago - 24/7 Wall Street

Giving The 'Thumbs Up' On Ardelyx

10 months ago - Seeking Alpha

Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

10 months ago - Zacks Investment Research

FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc.

10 months ago - PRNewsWire

Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

11 months ago - Zacks Investment Research

FREMONT, Calif., June 9, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for peo...

1 year ago - PRNewsWire

FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for peo...

1 year ago - PRNewsWire

Ardelyx: Sales Estimates For Tenapanor Suggest Upside In The Stock

1 year ago - Seeking Alpha

FREMONT, Calif., May 21, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for peo...

1 year ago - PRNewsWire

FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for peo...

1 year ago - PRNewsWire

As of late, it has definitely been a great time to be an investor Ardelyx

1 year ago - Zacks Investment Research

Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

1 year ago - Zacks Investment Research

Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

1 year ago - Zacks Investment Research

Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

1 year ago - Zacks Investment Research

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

1 year ago - Zacks Investment Research

Ardelyx: A Promising Cardiorenal Small Cap Pick For 2020

1 year ago - Seeking Alpha

With its first FDA approval in hand, a second, more lucrative indication looms on the horizon.

1 year ago - The Motley Fool

Investors reacted positively to the drugmaker's late-stage clinical results.

1 year ago - The Motley Fool

Ardelyx's Tenapanor Is A Long-Needed Alternative For A Cardiorenal Disease Complication

1 year ago - Seeking Alpha

Investors appear to be taking profits off the table after the biotech announced a key FDA approval.

1 year ago - The Motley Fool

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the tradename Ibsrela.

1 year ago - Zacks Investment Research

Ardelyx Inc. (NASDAQ: ARDX) shares dropped sharply on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) has approved its treatment of irritable bowel syndrome with constip...

1 year ago - 24/7 Wall Street

About ARDX

Ardelyx, Inc., a biopharmaceutical company, develops and sells medicines for the treatment of kidney and cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program that is in ... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2014
CEO
Michael Raab
Employees
129
Stock Exchange
NASDAQ
Ticker Symbol
ARDX
Full Company Profile

Financial Performance

In 2020, Ardelyx's revenue was $7.57 million, an increase of 43.36% compared to the previous year's $5.28 million. Losses were -$94.31 million, -0.66% less than in 2019.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Ardelyx stock is "Strong Buy." The 12-month stock price forecast is 14.14, which is an increase of 97.76% from the latest price.

Price Target
$14.14
(97.76% upside)
Analyst Consensus: Strong Buy